923 / 1631
Double Expressers
Johnson N A et al. JCO 2012;30:3452-3459
1.0
0.8
0.6
0.2
0.0
0.4
Overall Survival (Proportion)
OS (years)
0
3
5
8
10
Other (n=236)
MYC
+
/BCL2
+
(n=55)
DHIT (n=14)
P
< .001
*
P
= 0.14 (MYC
+
/BCL2
+
v
other)
• Not recognised as a distinct
entity. Biomarker for poor
response
• Different IHC thresholds
• No prospective trials
• Priority for clinical
investigations with novel
agents
• At present R-CHOP